Physician profile
Orrin M Troum
NPI 1821032608
$1,764,683.01
in general payments reported to CMS, 2019-2025
65 companies · $322K in 2025
The $322K reported for 2025 was more than what 99% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $344K · 2020: $169K · 2021: $142K · 2022: $272K · 2023: $250K · 2024: $265K · 2025: $322K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $495K · Consulting Fee: $128K · Travel and Lodging: $106K · Honoraria: $74K · Food and Beverage: $34K · Education: $267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $495,340.33 |
| Consulting Fee | $127,597.63 |
| Travel and Lodging | $106,226.89 |
| Honoraria | $73,827.83 |
| Food and Beverage | $34,055.92 |
| Education | $266.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $491,458.73 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Horizon Therapeutics Plc | $370,042.67 | 2019-2023 | Krystexxa |
| Amgen INC. | $228,899.19 | 2019-2025 | Krystexxa, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $153,637.17 | 2019-2025 | Ilaris, Cosentyx |
| Lilly USA, LLC | $124,418.56 | 2019-2025 | Taltz, Zepbound |
| Genzyme Corporation | $110,409.33 | 2019-2025 | |
| Ucb, INC. | $67,232.29 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $52,872.00 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $38,282.29 | 2019-2025 | Orencia |
| Celgene Corporation | $28,651.06 | 2019 | |
| Eli Lilly and Company | $21,236.69 | 2024-2025 | Taltz, Mounjaro |
| Janssen Scientific Affairs, LLC | $14,208.16 | 2019-2025 | Tremfya |
| Glaxosmithkline, LLC. | $10,920.97 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $9,680.97 | 2019-2025 | Actemra, Gazyva |
| Pacira Pharmaceuticals Incorporated | $9,440.42 | 2021-2024 |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $9,215.60 | 2019-2025 | |
| Janssen Biotech, INC. | $8,303.95 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Mallinckrodt Hospital Products INC. | $2,513.72 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals Lp | $1,735.41 | 2019-2025 | Saphnelo |
| Pacira Therapeutics, INC. | $1,586.66 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $1,395.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,069.12 | 2019-2025 | Ofev, Cyltezo |
| Genentech, INC. | $809.01 | 2025 | |
| Depuy Synthes Sales INC. | $634.98 | 2019-2025 | Monovisc |
| Ucb Sa | $570.00 | 2023 | Bimzelx |
| Ani Pharmaceuticals, INC. | $527.05 | 2022-2025 | Purified Cortrophin Gel, Sovuna |
| Radius Health, INC. | $525.88 | 2019-2025 | Tymlos |
| Bioventus LLC | $437.26 | 2019-2025 | Durolane, Xcell, Durolane |
| Antares Pharma, INC. | $379.46 | 2019-2021 | |
| Assertio Therapeutics, INC. | $354.72 | 2022 | |
| Mallinckrodt Enterprises LLC | $352.32 | 2019 | |
| Hikma Pharmaceuticals USA | $290.02 | 2019-2023 | Mitigare |
| Kiniksa Pharmaceuticals, Ltd. | $274.42 | 2021-2023 | Arcalyst |
| Fresenius Kabi USA, LLC | $272.09 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Alexion Pharmaceuticals, INC. | $263.26 | 2019-2025 | Strensiq |
| Redhill Biopharma INC. | $170.96 | 2020-2022 | |
| Medexus Pharma, INC. | $149.92 | 2019 | |
| Novo Nordisk INC | $129.08 | 2023 | Wegovy |
| Octapharma USA, INC. | $127.34 | 2021-2024 | Octagam Immune Globulin (Human), Panzyga |
| Scilex Pharmaceuticals INC. | $122.40 | 2024-2025 | |
| Alvogen INC | $116.03 | 2023-2025 | Teriparatide |
| Fidia Pharma USA INC. | $103.17 | 2024 | Hymovis, Triluron, Hyalgan |
| Takeda Pharmaceuticals U.S.A., INC. | $94.21 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $76.01 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $74.60 | 2019 | |
| Kyowa Kirin, INC. | $71.51 | 2023-2024 | Crysvita |
| Sandoz INC. | $57.03 | 2023-2025 | Hyrimoz, Jubbonti |
| Aurinia Pharma U.S., INC. | $53.13 | 2024 | Lupkynis |
| Celltrion USA INC. | $47.44 | 2023 | Yuflyma |
| Abbott Laboratories | $43.50 | 2025 | Eterna, Proclaim |
| Ibsa Pharma INC. | $43.06 | 2022-2024 | Licart, Tirosint |
| Vertiflex, INC. | $35.96 | 2019 | |
| Mindera Corp | $30.44 | 2025 | |
| Zyla Life Sciences, INC. | $30.31 | 2019 | |
| Organon LLC | $27.70 | 2024 | |
| Shionogi INC | $26.31 | 2019 | |
| Boston Scientific Corporation | $24.85 | 2022 | |
| Kedrion Biopharma, INC. | $24.63 | 2025 | Koate, Gammaked, Kedrab |
| Ferring Pharmaceuticals INC. | $24.17 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.12 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $21.44 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.29 | 2023 | Quviviq |
| Tonix Medicines, INC. | $16.97 | 2025 | Tonmya |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2,710.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orrin Troum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.